Orthovita submits new Cortoss clinical data to FDA

Recs

0

Special Offer!

Jan 12, Motley Fool Pro will accept new members for 10 days only. Your spot is reserved! To learn more, click below.

Orthovita Inc., an orthopedic and surgical products maker, said Tuesday it submitted additional clinical data about its Cortoss synthetic bone to the Food and Drug Administration.

Orthovita submitted two-year follow-up data from clinical trials of Cortoss Bone Augmentation Material. The company seeks 510(k) marketing approval for the product for use in vertebral augmentation.

Vertebral augmentation is a procedure in which material is added to a vertebra that has fractured due to injury or osteoporosis.

The company said the FDA asked for more data on Cortoss in March. The product has already been approved for use in the European Union.

Orthovita shares rose 15 cents, or 5.5 percent, to close at $2.90.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 729127, ~/articles/articlehandler.aspx, 1/7/2009 11:52:25 PM

Sign up for FREE Motley Fool site access to keep reading:

“Orthovita submits new Cortoss clinical data to FDA”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Most Recent

Most Recommended

Jan 7 at 4:08 PM

Market Summary

DJIA 8,769.70 -245.40 -2.72%
S&P 500 906.65 -28.05 -3.00%
NASD 1,599.06 -53.32 -3.23%
Sponsored by:

Related Tickers

Orthovita, Inc.

CAPS Rating 4/5 Stars

$3.47

-0.29 (-7.71%)

Outperform115

Underperform9

Rate This Stock